Alicia Ault

Alicia Ault is a journalist at Medscape who focuses on pharmaceutical news. She has a background in biology and experience reporting on healthcare topics, including drug development and regulatory issues. Her articles often cover new treatments and their potential impact on patients' lives.

Biography:  https://www.medscape.com/slideshow/2022-physicians-of-the-year-6015966

92%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

86%

Examples:

  • 40% to 50% of patients no longer needed CPAP device after taking tirzepatide.
  • Tirzepatide may be the first drug approved for OSA if it gains FDA approval.
  • Tirzepatide reduces sleep disruptions in patients with obesity and obstructive sleep apnea (OSA).
  • Zepbound reduced the number of sleep apnea episodes in patients both using and not using CPAP machines according to a trial.

Deceptions

75%

Examples:

  • The original SELECT trial evaluated the effect of semaglutide on patients with overweight or obesity and atherosclerotic cardiovascular disease on major adverse cardiovascular events (MACE). As previously reported by Medscape Medical News, the anti-obesity drug reduced MACE by around 20% vs placebo in this high-risk population.

Recent Articles

New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

New Drug Tirzepatide Shows Promise in Treating Obstructive Sleep Apnea, Reducing Need for CPAP Devices by 40-50%

Broke On: Tuesday, 25 June 2024 New clinical trials show that Eli Lilly's tirzepatide injection, used for diabetes and weight loss, significantly reduces sleep disruptions in obstructive sleep apnea patients. Up to 50% of trial participants no longer needed CPAP devices and experienced lower C-reactive protein levels, systolic blood pressure, and an average weight loss of 18%-20%. The SURMOUNT-OSA studies mark a major advancement in OSA treatment.
Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

Semaglutide: A Game-Changer in Weight Loss and Heart Health for Individuals with Cardiovascular Disease - SELECT Trial Results

Broke On: Sunday, 23 June 2024 Semaglutide, a weight-loss drug marketed as Wegovy or Ozempic, significantly reduces major adverse cardiovascular events (MACEs) by 20% for individuals with overweight or obesity and cardiovascular disease. The SELECT trial revealed that semaglutide users sustained weight loss for up to four years, dropped an average of 10% of their body weight, and showed improvements in heart health regardless of the amount lost. Semaglutide's benefits held up for all subgroups and normal A1c levels at baseline.